Literature DB >> 8568546

In vitro postantibiotic effect and postantibiotic leukocyte enhancement of tobramycin.

A Novelli1, T Mazzei, S Fallani, M I Cassetta, S Conti.   

Abstract

The occurrence of a postantibiotic effect (PAE) and postantibiotic leukocyte enhancement (PALE) of tobramycin, a natural aminoglycoside clinically used since the early 1970s, has been investigated in comparison to gentamicin on recent clinical isolates of Staphylococcus aureus (both methicillin-susceptible and -resistant strains) and of Gram-negative fermenting and non-fermenting rods. A concentration-dependent PAE was observed with both antibiotics, regardless of the bacterial species used, with some variability based on their intrinsic resistance. Tobramycin, at concentrations equal to or higher than the minimum inhibitory concentration (MIC), exhibited a rather long PAE (ranging from 1.9 to 10.9 h) which was often significantly longer than that observed with gentamicin (ranging from 1.0 to 7.5h). Moreover, pre-exposure to tobramycin led to enhanced polymorphonuclear leukocyte phagocytosis and killing with a 2- to 27-fold increase in activity compared to controls. These results suggest that tobramycin might be conveniently used with once-daily dosing for the treatment of infections due to sensitive pathogens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8568546     DOI: 10.1179/joc.1995.7.4.355

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  9 in total

1.  Postantibiotic leukocyte enhancement of meropenem against gram-positive and gram-negative strains.

Authors:  A Novelli; S Fallani; M I Cassetta; S Conti; T Mazzei
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

Review 2.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 3.  Pharmacological considerations for the proper clinical use of aminoglycosides.

Authors:  Spyridon Pagkalis; Elpis Mantadakis; Michael N Mavros; Christina Ammari; Matthew E Falagas
Journal:  Drugs       Date:  2011-12-03       Impact factor: 9.546

Review 4.  Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis.

Authors:  E Nestaas; H-J Bangstad; L Sandvik; K-O Wathne
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-04-27       Impact factor: 5.747

5.  Post-antibiotic effect of orbifloxacin against Escherichia coli and Pseudomonas aeruginosa isolates from dogs.

Authors:  Kazuki Harada; Takae Shimizu; Yasushi Kataoka; Toshio Takahashi
Journal:  Acta Vet Scand       Date:  2012-03-20       Impact factor: 1.695

6.  Prolonged Post-Discontinuation Antibiotic Exposure in Very Low Birth Weight Neonates at Risk for Early-Onset Sepsis.

Authors:  Jennifer Le; Rachel G Greenberg; Daniel K Benjamin; YoungJun Yoo; Kanecia O Zimmerman; Michael Cohen-Wolkowiez; Kelly C Wade
Journal:  J Pediatric Infect Dis Soc       Date:  2021-05-28       Impact factor: 5.235

7.  Optimal aminoglycoside therapy following the sepsis: how much is too much?

Authors:  Laleh Mahmoudi; Ramin Niknam; Sarah Mousavi; Arezoo Ahmadi; Hooshyar Honarmand; Shadi Ziaie; Mojtaba Mojtahedzadeh
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

Review 8.  A practical guide to the diagnosis, treatment, and prevention of neonatal infections.

Authors:  Roberto Parulan Santos; Debra Tristram
Journal:  Pediatr Clin North Am       Date:  2015-04       Impact factor: 3.278

Review 9.  Antibiotics and ECMO in the Adult Population-Persistent Challenges and Practical Guides.

Authors:  Francisco Gomez; Jesyree Veita; Krzysztof Laudanski
Journal:  Antibiotics (Basel)       Date:  2022-03-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.